Unique ID issued by UMIN | UMIN000010163 |
---|---|
Receipt number | R000011886 |
Scientific Title | Effects of Aliskiren and Amlodipine Combination Therapy or High-dose Amlodipine Monotherapy on Ambulatory Blood Pressure in Hypertensive Patients |
Date of disclosure of the study information | 2013/03/06 |
Last modified on | 2013/10/10 09:28:26 |
Effects of Aliskiren and Amlodipine Combination Therapy or High-dose Amlodipine Monotherapy on Ambulatory Blood Pressure in Hypertensive Patients
Aliskiren Combination with Amlodipine on Target Organ Damage: ACAT study
Effects of Aliskiren and Amlodipine Combination Therapy or High-dose Amlodipine Monotherapy on Ambulatory Blood Pressure in Hypertensive Patients
Aliskiren Combination with Amlodipine on Target Organ Damage: ACAT study
Japan |
Hypertension
Cardiology |
Others
NO
To investigate the additional effects of 150-300 mg aliskiren or 5mg amlodipine on 24-hour ambulatory blood pressure and vascular function in uncontrolled hypertensive patients with 5mg amlodipine monotherapy.
Efficacy
Ambulatory blood pressure monitoring (ABPM)
Pulse wave velocity (PWV)
Clinic BP, home BP, endothelial function (flow-mediated dilatation), plasma renin activity, plasma aldosterone, microalbuminuria, urinary sodium excretion, NT pro-BNP, high-sensitive CRP, high-sensitive troponin-T, cystatin C.
Interventional
Parallel
Randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
After 5mg amlodipine monotherapy for 4 weeks run-in period, 150mg aliskiren is added for first 8 weeks, and dose of aliskiren is doubled to 300mg for next 8 weeks.
After 5mg amlodipine monotherapy for 4 weeks run-in period, dose of amlodipine is doubled to 10mg throughout 16 weeks treatment period.
20 | years-old | < |
Not applicable |
Male and Female
Patients with clinic or home BP > 140mmHg in systolic and/or > 90mmHg in diastolic (systolic BP > 130mmHg and/or diastolic BP > 85mmHg in case of diabetes), although receiving 5mg amlodipine monotherapy for 4 weeks period or more.
1) Secondary hypertension
2) Moderate to severe symptom of heart failure (New York Heart Association >class III), fatal arrhythmia
3) A history of stroke, myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft within the past 6 months
4) Severe renal dysfunction (eGFR <30ml/min/1.73m2, or serum creatinine >2.0mg/dl)
5) Severe hepatic disease
6) Uncontrolled diabetes (HbA1c >12%)
7) Pregnant women
8) A history of allergy/hypersensitivity to dihydropyridine calcium channel blockers
9) Patients receiving other antihypertensive drugs than amlodipine
10) Patients receiving P-glycoprotein inhibitor
11) Severe dementia
12) Not eligible for this study based on the decision's of a physician
110
1st name | |
Middle name | |
Last name | Kazuomi Kario |
Jichi Medical University School of Medicine
Division of Cardiovascular Medicine, Department of Medicine
3311-1, Yakushiji, Shimotsuke, Tochigi
1st name | |
Middle name | |
Last name |
Jichi Medical University School of Medicine
Division of Cardiovascular Medicine, Department of Medicine
0285-58-7344
kkario@jichi.ac.jp
Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical
University School of Medicine.
Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical
University School of Medicine.
Other
Fukushima Prefectural Miyashita Hospital
Yanai Municipal Heigun Clinic
NO
福島県立宮下病院 (福島県), 柳井市立平郡診療所 (山口県).
2013 | Year | 03 | Month | 06 | Day |
Unpublished
Completed
2011 | Year | 03 | Month | 01 | Day |
2011 | Year | 04 | Month | 01 | Day |
2013 | Year | 03 | Month | 05 | Day |
2013 | Year | 10 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011886